Treatment of Testosterone deficiency in men with Sleep Apnoea Syndrome utilising Nebido therapy.

ikolai Sleep Monitoring Clinic0 个研究点开始时间: 2008年6月18日最近更新: 2012年7月24日

试验速览

暂无简介。

•20 hypogonadal men requiring Nebido therapy who have proven sleep apnoea syndrome
•Hypogonadism is defined as:
•Total testosterone of <8 nmol or free testosterone of < 180 pmol/L
•Total testosterone between 8-12 nmol/L or free testesterone .180-250 pmol/L who are symptomatic of hypogonadism:
•- Diminished libido and erectile quality and frequency
•-Changes in mood and cognitive ability
•-Sleep disturbance
•-Decrease in lean body mass
•-Increase in visceral fat
•-Decrease in body hair and skin alterations
•-Dearcreased bone mineral density
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•The patients are ineligible for the study if there is a current or past history of:
•- Androgen dependent carcinoma of prostate or male mammary galnd
•-Liver tumours
•-Hypersensitivity to Nebido or any of its incipients
•-Symptoms or signs of prostatic enlargement
•-Polycythaemia (Haematocrit of 55% or more)
•-Any general systemic illness
•-Severe cardiac, hepatic or renal insufficiency
•or those deemed unable to comply with the requirements of the protocol

发起方

ikolai Sleep Monitoring Clinic